New drug combination extends survival with advanced kidney cancer. It’s poised to enter a competitive treatment market

first_imgBiotech [email protected] Log In | Learn More New drug combination extends survival with advanced kidney cancer. It’s poised to enter a competitive treatment market STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. First 30 days free. GET STARTED Adam Feuerstein Patients with advanced kidney cancer live longer when treated with a combination of drugs from Bristol Myers Squibb and Exelixis compared to an older medicine, according to new clinical trial results reported Sunday.Convincing physicians to prescribe the new combination regimen for kidney cancer patients, though, will face a challenge: equally effective treatments already in use. GET STARTED What is it?center_img About the Author Reprints Adobe Senior Writer, Biotech Adam is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He’s also a co-host of “The Readout LOUD” podcast. What’s included? By Adam Feuerstein Sept. 19, 2020 Reprints Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. @adamfeuerstein Tags biotechnologycancerESMO20pharmaceuticalsSTAT+last_img read more